ÌÇÐÄÓ°ÊÓ
Home
ÌÇÐÄÓ°ÊÓ
Back
ÌÇÐÄÓ°ÊÓ
Contact Us
Patient Inquiry
Meet the Team
Back
Senior Leadership
Board of Directors
Scientific Advisory Board
Adam's Story
Privacy Policy
Careers & Culture
Technology
Back
mRNA Medicines Platform
INTENTâ„¢ LNP Platform
Manufacturing Platform
Pipeline
Business Development
Back
Partnerships
News
Back
Press Releases
Publications
Culture
Back
Careers
Home
ÌÇÐÄÓ°ÊÓ
ÌÇÐÄÓ°ÊÓ
Contact Us
Patient Inquiry
Meet the Team
Senior Leadership
Board of Directors
Scientific Advisory Board
Adam's Story
Privacy Policy
Careers & Culture
Technology
mRNA Medicines Platform
INTENTâ„¢ LNP Platform
Manufacturing Platform
Pipeline
Business Development
Partnerships
News
Press Releases
Publications
Culture
Careers
Publications
and Scientific Papers
All
2026
2025
2024
2023
2022
Enabling Translational Immunotherapy Through Non-Viral Delivery to Immune Cells
Read more
INTENTâ„¢ LNPs Induce Effective Anti-Tumor T cell Responses
Read more
An INTENTâ„¢ LNP Reagent for Targeted mRNA Transfection of Dendritic Cells and Macrophages
Read more
Process development of tangential flow filtration and sterile filtration for manufacturing of mRNA-lipid nanoparticles: A study on membrane performance and filtration modeling
Read more
Comparison of a SARS-CoV-2 mRNA booster immunization containing additional antigens to a spike-based mRNA vaccine against Omicron BA.5 infection in hACE2 mice
Read more
A bivalent COVID-19 mRNA vaccine elicited broad immune responses and protection against Omicron subvariants infection
Read more
Therapeutic mRNA cancer vaccine for GBM reaches complete response in a pre-clinical model
Read more
Comparison of modified T7 RNAPs to develop a simplified, cost effective, robust mRNA production process
Read more
Novel LNP delivered mRNA vaccine elicits potent immune responses and cures established tumor in mice
Read more
Next-Generation LNP's Induce Effective Anti-Tumor T cell Responses
Read more
Next-Generation mRNA-LNP Vaccine Prototype Achieves Tumor Clearance in a GBM Mouse Model
Read more
Comparable safety and non-inferior immunogenicity of the SARS-CoV-2 mRNA vaccine candidate PTX-COVID19-B and BNT162b2 in a phase 2 randomized, observer-blinded study
Read more
Phase I randomized, observer‑blinded, placebo‑controlled study of a SARS‑CoV‑2 mRNA vaccine PTX‑COVID19‑B
Read more
In vivo Characterization of T-Cell Activating Disulfide Lipids
Read more
Preclinical Evaluation of a SARS-CoV-2 mRNA Vaccine PTX-COVID19-B
Read more